Navigation Links
ViroPharma to Present at Several Upcoming Healthcare Conferences
Date:9/3/2009

ibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
2. ViroPharma to Present at Two June Healthcare Conferences
3. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
6. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
7. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
8. ViroPharma to Present at Three November Healthcare Conferences
9. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
10. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
11. ViroPharma to Present at Three October Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Martek Biosciences Corporation (Nasdaq: MATK ) ... and fiscal year ended October 31, 2009. Revenues for ... $90.4 million in the fourth quarter of fiscal 2008. ... share, for the fourth quarter of fiscal 2009, a ... diluted share, in last year,s fourth quarter. The ...
(Date:12/16/2009)... among the Best in the Nation ,, ... proudly announces it has been granted Magnet(R) recognition ... Recognition Program(R). Magnet(R) is one of the highest ... can achieve, and places Hahnemann among the five ... achieved this prestigious distinction. ,, At 9:00 am ...
(Date:12/16/2009)... Cord Blood America, Inc. (OTC Bulletin ... preservation company ( http://www.cordblood-america.com ) focused on ... a biological insurance policy, to families nationwide and ... debt by a total of $1.4 million so ... total debt eliminated for the year now tops ...
(Date:12/16/2009)... Mass., Dec. 16 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that, according ... Stelara and Abbott,s briakinumab (both interleukin inhibitors) will ... 2012 in the drug market for moderate to ... experience greater uptake, capturing nearly three times as ...
Breaking Biology Technology:Martek Announces Fourth Quarter and FY 2009 Financial Results 2Martek Announces Fourth Quarter and FY 2009 Financial Results 3Martek Announces Fourth Quarter and FY 2009 Financial Results 4Martek Announces Fourth Quarter and FY 2009 Financial Results 5Martek Announces Fourth Quarter and FY 2009 Financial Results 6Martek Announces Fourth Quarter and FY 2009 Financial Results 7Martek Announces Fourth Quarter and FY 2009 Financial Results 8Martek Announces Fourth Quarter and FY 2009 Financial Results 9Martek Announces Fourth Quarter and FY 2009 Financial Results 10Martek Announces Fourth Quarter and FY 2009 Financial Results 11Martek Announces Fourth Quarter and FY 2009 Financial Results 12Martek Announces Fourth Quarter and FY 2009 Financial Results 13Martek Announces Fourth Quarter and FY 2009 Financial Results 14Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Cord Blood America Says 2009 Debt Reduction Tops $10 Million 2Cord Blood America Says 2009 Debt Reduction Tops $10 Million 3In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 2In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market 3
... HOUSTON, July 16 US Oncology Holdings, Inc. ... 2008 second quarter,financial results on Thursday, August 7, ... has been scheduled at 11:00,a.m., EDT, for the ... In this call, representatives of US Oncology,s management,team ...
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced ... results on Wednesday, July 23,2008, after the market closes. ... at 2:00 p.m. PT, which will be open to ... the company will review,the financial results and discuss other ...
... July 16 The Brazilian Sugarcane,Industry Association (UNICA) ... Policies" as another major report that highlights the,benefits ... reduction and,urges governments to level the playing field ... weeks, reports by diverse organizations such as FAO, ...
Other Biology Technology:Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 2Sangamo BioSciences Announces Second Quarter Conference Call and Webcast 3Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol 2Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol 3
(Date:12/16/2009)... Dec. 8, 2009 National Instruments ... industrial measurement and control, and DENSO Robotics, ... using robotics technology, today announced their collaboration ... with DENSO robotic arms. The collaboration increases ... and flexible manufacturing applications. In today,s trend ...
(Date:12/15/2009)... LONDON, Dec. 15 The 2009 ... Innovation Award is presented to Sagem Securite ... Control systems. The award recognises the company,s ... continuous stewardship in offering novel, value-added products ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, "Sagem Securite has ...
(Date:12/15/2009)... environmental impacts, social dynamics, and production levels are ... of an agroecosystem. Positive or negative, these factors ... social groups to continuously adapt farming and food ... learning theory suggests that knowledge is gained as ... are especially valuable for environmental and agricultural educators ...
Breaking Biology News(10 mins):National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 5Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4Experiential learning teaches change and adaptation 2Arena Pharmaceuticals to Host Conference Call and Webcast on Friday September 18 2009 to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaser 5016 1Arena Pharmaceuticals to Host Conference Call and Webcast on Friday September 18 2009 to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaser 5016 2Arena Pharmaceuticals to Host Conference Call and Webcast on Friday September 18 2009 to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaser 5016 3Study Links Epilepsy to Brain Protein 57562 1Lack of Insurance to Blame for Almost 45 000 Deaths 3A Study 57560 1Lack of Insurance to Blame for Almost 45 000 Deaths 3A Study 57560 2Lack of Insurance to Blame for Almost 45 000 Deaths 3A Study 57560 3
... Columbia University's Mailman School of Public Health, the Centers ... Research Center have discovered a key mechanism by which ... identification of an amino acid sequence in Filoviruses that ... described in the December 2006 issue of The FASEB ...
... cheap, quick and copyright-respecting way to turn existing print ... in an experimental beta version for free download, is ... the most popular computer operating systems. , "Brain ... says Gully A.P.C. Burns, a specialist in neuroinformatics who ...
... levels of the virus associated with cervical cancer can ... according to a study published in the November 2006 ... Anthony Gunnell, a medical biostatistician and epidemiologist and colleagues ... exams of women with non-invasive cervical cancer in situ ...
Other Biology News:Researchers discover key mechanism by which lethal viruses Ebola and Marburg cause disease 2Beyond the book: Software automates access to brain atlases 2Beyond the book: Software automates access to brain atlases 3High HPV concentrations combined with smoking significantly raise risks of cervical cancer 2High HPV concentrations combined with smoking significantly raise risks of cervical cancer 3
... NOBLE BSA-Free Stabilizer is a bovine ... It is an aqueous solution ... a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... a combination of 0.02% methylisothiazolone and ...
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
... software with the DeCypher Engine accelerator cards to ... perform searches like these from your desktop: ... under 6 days Align BAC-sized queries ... HMM analysis to compare 100,000 sequences to PFAM ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: